357 related articles for article (PubMed ID: 22419019)
1. Activation of alternative pathways of angiogenesis and involvement of stem cells following anti-angiogenesis treatment in glioma.
Arbab AS
Histol Histopathol; 2012 May; 27(5):549-57. PubMed ID: 22419019
[TBL] [Abstract][Full Text] [Related]
2. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
3. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
4. Effects of targeting the VEGF and PDGF pathways in diffuse orthotopic glioma models.
Navis AC; Hamans BC; Claes A; Heerschap A; Jeuken JW; Wesseling P; Leenders WP
J Pathol; 2011 Apr; 223(5):626-34. PubMed ID: 21341272
[TBL] [Abstract][Full Text] [Related]
5. Anti-angiogenic approaches to malignant gliomas.
Soffietti R; Trevisan E; Bertero L; Bosa C; Ruda R
Curr Cancer Drug Targets; 2012 Mar; 12(3):279-88. PubMed ID: 22229250
[TBL] [Abstract][Full Text] [Related]
6. Anti-VEGF therapies for malignant glioma: treatment effects and escape mechanisms.
Miletic H; Niclou SP; Johansson M; Bjerkvig R
Expert Opin Ther Targets; 2009 Apr; 13(4):455-68. PubMed ID: 19335067
[TBL] [Abstract][Full Text] [Related]
7. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
Zhao Y; Adjei AA
Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
[TBL] [Abstract][Full Text] [Related]
8. Angiogenesis and anti-angiogenic molecularly targeted therapies in malignant gliomas.
Argyriou AA; Giannopoulou E; Kalofonos HP
Oncology; 2009; 77(1):1-11. PubMed ID: 19439998
[TBL] [Abstract][Full Text] [Related]
9. Angiogenesis as a therapeutic target in malignant gliomas.
Chi AS; Sorensen AG; Jain RK; Batchelor TT
Oncologist; 2009 Jun; 14(6):621-36. PubMed ID: 19487335
[TBL] [Abstract][Full Text] [Related]
10. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.
Plate KH; Scholz A; Dumont DJ
Acta Neuropathol; 2012 Dec; 124(6):763-75. PubMed ID: 23143192
[TBL] [Abstract][Full Text] [Related]
11. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor.
Shibuya M
FEBS J; 2009 Sep; 276(17):4636-43. PubMed ID: 19664071
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for high-grade gliomas.
Chamberlain MC; Raizer J
CNS Neurol Disord Drug Targets; 2009 Jun; 8(3):184-94. PubMed ID: 19601816
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
[TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
Takahashi S
Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis and antiangiogenic therapy for malignant gliomas.
Takano S; Kamiyama H; Tsuboi K; Matsumura A
Brain Tumor Pathol; 2004; 21(2):69-73. PubMed ID: 15700836
[TBL] [Abstract][Full Text] [Related]
16. Angiogenesis factors in gliomas: a new key to tumour therapy?
Mentlein R; Held-Feindt J
Naturwissenschaften; 2003 Sep; 90(9):385-94. PubMed ID: 14504780
[TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy.
Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X
Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053
[TBL] [Abstract][Full Text] [Related]
18. Anti-angiogenic treatment strategies for malignant brain tumors.
Kirsch M; Schackert G; Black PM
J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274
[TBL] [Abstract][Full Text] [Related]
19. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
Kurzrock R; Stewart DJ
Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
[TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Gacche RN; Meshram RJ
Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
